Advancing the Future of TAVR: Real-World Insights on the ScienCrown System at CSI Asia-Pacific 2026

We are thrilled to share highlights from an outstanding presentation delivered by Prof. Yang Chen from Prof. Yongjian Wu's team (Fuwai Hospital, National Center for Cardiovascular Diseases) at CSI Asia-Pacific 2026 in Bangkok！

Prof. Yang Chen delivered a comprehensive overview of the ScienCrown Transcatheter Aortic Valve System, a novel fully-retrievable, self-expanding short-frame valve that is redefining structural heart intervention.

Key Presentation Highlights:

Innovative Design & Core Technology:

The ScienCrown system features a world-first Mortise-and-Tenon Full-Coupling Connection Design. This patented technology enables 100% full expansion and 100% full recapture, solving the bouncing issue of traditional self-expanding valves and ensuring accurate positioning.

Robust Clinical Trial Results (1-Year Follow-up):

• Device success rate: 99.2%

• Procedural success rate: 96.88%

• All-cause mortality (1-year): 5.47%

• Moderate or greater PVL: 2.34% (1-year)

• Effective orifice area (1-year): 1.88 cm², with a transvalvular pressure gradient of 10.51 mmHg.

Looking Ahead: Pure Aortic Regurgitation:

The presentation also highlighted a proof-of-concept study exploring ScienCrown for pure aortic regurgitation. With a 100% implantation success rate across 24 patients (16 transapical, 8 transfemoral), the tubular anchoring zone and stopper profile show promising potential for this challenging patient population.

A huge thank you to Prof. Yang Chen for sharing these valuable real-world clinical insights on behalf of Prof. Wu's team! We are proud to see how Chinese original innovation is contributing to the global advancement of TAVR therapy.